About
MedAnnex is a clinical-stage biopharmaceutical company developing MDX-124, a monoclonal antibody that targets annexin-A1 to inhibit cancer cell proliferation and migration, with ongoing trials in cancer and plans for autoimmune disease therapies.
Explore MedAnnex's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.